Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

Inclusion Criteria:

• ≥ 18 years of age at the time of signing the informed consent

• Diagnosed with Dialysis-dependent End-Stage Kidney Disease (ESKD)

• A candidate for kidney transplant from:

1. Donation after Circulatory Death (DCD) donor

2. High-risk Donation after Brain Death (DBD) donor

Exclusion Criteria:

• Is to receive a kidney from a donor with category I,II,IV and V MaastrichtClassification

• Diagnosed with Acute Kidney Injury (AKI) of Stage 3 severity according to the KidneyDisease: Improving Global Outcomes (KDIGO) guidelines.